Boston Scientific
Market Cap
US$60.7b
Last Updated
2020/01/24 23:32 UTC
Data Sources
Company Financials +
Executive Summary
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with proven track record.
Similar Companies
Share Price & News
How has Boston Scientific's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BSX has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-2.4%
BSX
-0.4%
US Medical Equipment
-1.3%
US Market
1 Year Return
15.4%
BSX
27.3%
US Medical Equipment
22.0%
US Market
Return vs Industry: BSX underperformed the US Medical Equipment industry which returned 28.4% over the past year.
Return vs Market: BSX underperformed the US Market which returned 24.7% over the past year.
Shareholder returns
| BSX | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.4% | -0.4% | -1.3% |
| 30 Day | -4.6% | 2.8% | 1.8% |
| 90 Day | 5.8% | 11.8% | 9.3% |
| 1 Year | 15.4%15.4% | 28.3%27.3% | 24.6%22.0% |
| 3 Year | 81.0%81.0% | 91.8%86.3% | 49.2%39.6% |
| 5 Year | 191.8%191.8% | 131.2%106.5% | 77.9%58.3% |
Price Volatility Vs. Market
How volatile is Boston Scientific's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
Despite Its High P/E Ratio, Is Boston Scientific Corporation (NYSE:BSX) Still Undervalued?1 week ago | Simply Wall St
Don’t Buy Boston Scientific Corporation (NYSE:BSX) Until You Understand Its ROCE3 weeks ago | Simply Wall St
Boston Scientific (NYSE:BSX) Is Growing Earnings But Are They A Good Guide?Valuation
Is Boston Scientific undervalued compared to its fair value and its price relative to the market?
0.7%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BSX ($43.21) is trading below our estimate of fair value ($43.5)
Significantly Below Fair Value: BSX is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: BSX is poor value based on its PE Ratio (54.4x) compared to the Medical Equipment industry average (46.3x).
PE vs Market: BSX is poor value based on its PE Ratio (54.4x) compared to the US market (18.9x).
Price to Earnings Growth Ratio
PEG Ratio: BSX is poor value based on its PEG Ratio (1.9x)
Price to Book Ratio
PB vs Industry: BSX is overvalued based on its PB Ratio (6.1x) compared to the US Medical Equipment industry average (4.1x).
Next Steps
Future Growth
How is Boston Scientific forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?
28.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BSX's forecast earnings growth (28.1% per year) is above the savings rate (1.7%).
Earnings vs Market: BSX's earnings (28.1% per year) are forecast to grow faster than the US market (14.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BSX's revenue (8.8% per year) is forecast to grow faster than the US market (7.5% per year).
High Growth Revenue: BSX's revenue (8.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BSX's Return on Equity is forecast to be high in 3 years time (26.9%)
Next Steps
Past Performance
How has Boston Scientific performed over the past 5 years?
60.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BSX has a large one-off loss of $475.0M impacting its September 30 2019 financial results.
Growing Profit Margin: BSX's current net profit margins (10.5%) are higher than last year (6.9%).
Past Earnings Growth Analysis
Earnings Trend: BSX's earnings have grown significantly by 60.6% per year over the past 5 years.
Accelerating Growth: BSX's earnings growth over the past year (62.7%) exceeds its 5-year average (60.6% per year).
Earnings vs Industry: BSX earnings growth over the past year (62.7%) exceeded the Medical Equipment industry 31%.
Return on Equity
High ROE: BSX's Return on Equity (11.2%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Boston Scientific's financial position?
Financial Position Analysis
Short Term Liabilities: BSX's short term assets ($4.8B) exceed its short term liabilities ($4.3B).
Long Term Liabilities: BSX's short term assets ($4.8B) do not cover its long term liabilities ($12.8B).
Debt to Equity History and Analysis
Debt Level: BSX's debt to equity ratio (112.2%) is considered high.
Reducing Debt: BSX's debt to equity ratio has increased from 63.5% to 112.2% over the past 5 years.
Debt Coverage: BSX's debt is not well covered by operating cash flow (10.7%).
Interest Coverage: BSX's interest payments on its debt are well covered by EBIT (5.4x coverage).
Balance Sheet
Inventory Level: BSX has a low level of unsold assets or inventory.
Debt Coverage by Assets: BSX's debt is not covered by short term assets (assets are 0.4x debt).
Next Steps
Dividend
What is Boston Scientific's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate BSX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BSX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BSX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BSX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BSX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Boston Scientific's salary, the management and board of directors tenure and is there insider trading?
6.0yrs
Average management tenure
CEO
Mike Mahoney (54yo)
7.2yrs
Tenure
US$13,970,901
Compensation
Mr. Michael F. Mahoney, also known as Mike, has been Chairman of Boston Scientific Corporation since May 3, 2016, its Chief Executive Officer since November 1, 2012 and has been its President since October ...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD13.97M) is about average for companies of similar size in the US market ($USD10.78M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
Management Age and Tenure
6.0yrs
Average Tenure
53.5yo
Average Age
Experienced Management: BSX's management team is seasoned and experienced (6 years average tenure).
Board Age and Tenure
4.6yrs
Average Tenure
62yo
Average Age
Experienced Board: BSX's board of directors are considered experienced (4.6 years average tenure).
Insider Trading
Insider Buying: BSX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Shares | 12,621 |
| Max Price | US$42.70 |
| Entity | Individual |
| Shares | 4,800 |
| Max Price | US$42.58 |
| Entity | Individual |
| Shares | 1,104 |
| Max Price | US$40.75 |
| Entity | Individual |
| Shares | 2,455 |
| Max Price | US$41.98 |
| Entity | Individual |
| Shares | 6,000 |
| Max Price | US$42.79 |
| Entity | Individual |
| Shares | 22,047 |
| Max Price | US$38.03 |
| Entity | Individual |
| Role | Chief Information Officer Senior VP & Chief Information Officer |
| Shares | 7,803 |
| Max Price | US$38.42 |
| Entity | Individual |
| Shares | 11,980 |
| Max Price | US$39.94 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Joe Fitzgerald (55yo)
Executive VP & President of Rhythm Management
- Tenure: 9.9yrs
- Compensation: US$4.04m
Dan Brennan (53yo)
Executive VP & CFO
- Tenure: 6yrs
- Compensation: US$3.67m
Susie Lisa
Vice President of Investor Relations
- Tenure: 6.1yrs
Mike Mahoney (54yo)
Chairman
- Tenure: 7.2yrs
- Compensation: US$13.97m
Dave Pierce (55yo)
Executive VP & President of MedSurg
- Tenure: 9yrs
- Compensation: US$2.73m
Kevin Ballinger (46yo)
Executive VP & President of Interventional Cardiology
- Tenure: 7yrs
- Compensation: US$2.84m
Ed Mackey (56yo)
Executive VP of Operations
- Tenure: 4.9yrs
- Compensation: US$3.82m
Desiree Ralls-Morrison (52yo)
Senior VP
- Tenure: 2.2yrs
Jodi Eddy (46yo)
Senior VP & Chief Information Officer
- Tenure: 4.1yrs
Jonathan Monson
VP, Global Controller & Chief Accounting Officer
- Tenure: 0.5yrs
Board Members
Edward Ludwig (68yo)
Lead Independent Director
- Tenure: 3.7yrs
- Compensation: US$340.21k
Donna James (62yo)
Independent Director
- Tenure: 4.5yrs
- Compensation: US$309.98k
Steve MacMillan (55yo)
Independent Director
- Tenure: 4.8yrs
- Compensation: US$294.98k
Dave Roux (62yo)
Independent Director
- Tenure: 6yrs
- Compensation: US$315.51k
Ellen Zane (67yo)
Independent Director
- Tenure: 3.8yrs
- Compensation: US$294.98k
Yoshiaki Fujimori (68yo)
Independent Director
- Tenure: 3.5yrs
- Compensation: US$294.98k
Charles Dockendorff (65yo)
Independent Director
- Tenure: 4.8yrs
- Compensation: US$318.31k
Nelda Connors (53yo)
Independent Director
- Tenure: 10.1yrs
- Compensation: US$297.48k
John Sununu (54yo)
Independent Director
- Tenure: 10.8yrs
- Compensation: US$315.16k
Mike Mahoney (54yo)
Chairman
- Tenure: 7.2yrs
- Compensation: US$13.97m
Company Information
Boston Scientific Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Boston Scientific Corporation
- Ticker: BSX
- Exchange: NYSE
- Founded: 1979
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$60.729b
- Shares outstanding: 1.39b
- Website: https://www.bostonscientific.com
Number of Employees
Location
- Boston Scientific Corporation
- 300 Boston Scientific Way
- Marlborough
- Massachusetts
- 1752
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BSX | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | May 1992 |
| BSX | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | May 1992 |
| BSX * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | May 1992 |
| 0HOY | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | May 1992 |
| BSX | ETLX (Eurotlx) | Yes | Common Stock | IT | EUR | May 1992 |
| BSXC | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | May 1992 |
| B1SX34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH REPR 1 COM | BR | BRL | Dec 2019 |
Biography
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/01/24 23:32 |
| End of Day Share Price | 2020/01/24 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.